ArticleZhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi2026
[Clinical analysis of bendamustine combined with rituximab as first-line therapy for B-cell lymphoproliferative disorders other than follicular lymphoma].
Article in Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This study aimed to evaluate the efficacy and safety of bendamustine combined with rituximab as first-line therapy in B-cell lymphoproliferative disorders (BLPD) other than follicular lymphoma (FL). Based on the Lymphoma Subcohort of the National Hematological Disease Cohort Study, a total of 91 newly diagnosed patients with non-FL BLPD receiving frontline bendamustine-rituximab regimen at the Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences from August 2019 to February 2025 were enrolled.The median age of the cohort was 59 years (range, 30 - 79 years), with a male-to-female ratio of 1.6:1 (56 males and 35 females). Among all subjects, 78 patients completed ≥ 2 cycles of induction therapy, with a best complete response (CR) rate of 59.0% and an objective response rate of 88.5%. The primary grade 3 - 4 hematological adverse events included neutropenia, lymphopenia, anemia and thrombocytopenia, while common non-hematological adverse events consisted of fever, infection and abnormal liver function. With a median follow-up duration of 41 months (range, 2 - 70 months), the 5-year progression-free survival (PFS) rate and 5-year overall survival (OS) rate were 78.1% (95%
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.